Siga Technologies Inc (SIGA): Revenue
$94.57M
Year ended 2025-12-31
$53.66M
Trailing 12 months to 2026-06-30
-5.1%
3-year compound annual growth
-5.4%
5-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $94.57M | -31.8% | 2026-03-10, From 2025-01-01 |
| 2024-12-31 | $138.72M | -0.9% | 2026-03-10, From 2024-01-01 |
| 2023-12-31 | $139.92M | +26.3% | 2026-03-10, From 2023-01-01 |
| 2022-12-31 | $110.78M | -17.1% | 2025-03-11, From 2022-01-01 |
| 2021-12-31 | $133.67M | +7.0% | 2024-03-12, From 2021-01-01 |
| 2020-12-31 | $124.96M | +367.3% | 2023-03-02, From 2020-01-01 |
| 2019-12-31 | $26.74M | -94.4% | 2022-03-03, From 2019-01-01 |
| 2018-12-31 | $477.05M | n/m | 2021-03-04, From 2018-01-01 |
| 2017-12-31 | $12.27M | -18.1% | 2020-03-05, From 2017-01-01 |
| 2016-12-31 | $14.99M | n/a | 2019-03-06, From 2016-01-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| Siga Technologies Inc (SIGA) | 2025-12-31 | $94.57M | -31.8% |
| Cytokinetics Inc (CYTK) | 2025-12-31 | $88.04M | +376.6% |
| Standard Biotools Inc. (LAB) | 2025-12-31 | $85.33M | -6.2% |
| Zymeworks Inc. (ZYME) | 2025-12-31 | $105.97M | +38.9% |
| ARS Pharmaceuticals, Inc. (SPRY) | 2025-12-31 | $84.28M | -5.5% |
| Zevra Therapeutics, Inc. (ZVRA) | 2025-12-31 | $106.47M | +350.9% |
| Nurix Therapeutics, Inc. (NRIX) | 2025-11-30 | $83.98M | +54.0% |
| Theravance Biopharma, Inc. (TBPH) | 2025-12-31 | $107.46M | +66.9% |
| Arcturus Therapeutics Holdings Inc. (ARCT) | 2025-12-31 | $82.03M | -46.1% |
Compare SIGA, CYTK, LAB, ZYME side by side · Screen every company in Pharmaceutical Preparations ↗